There's nothing new about the corporate quest to capitalize on growth in emerging economies. For GlaxoSmithKline (NYSE:GSK), which is increasing its stake in both in its Indian and Nigerian consumer health businesses, emerging economies provide an opportunity to boost otherwise stagnant revenue trends within its core pharmaceuticals business in the U.S. and Europe. In the following video, health care bureau chief Brenton Flynn runs through the Glaxo news and highlights some other big pharma players targeting emerging markets to spur growth going forward: Johnson & Johnson (NYSE:JNJ) and Abbott Laboratories (NYSE:ABT).
Brenton Flynn has no positions in the stocks mentioned above. The Motley Fool owns shares of GlaxoSmithKline and Johnson & Johnson. Motley Fool newsletter services recommend GlaxoSmithKline and Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.
